ReviewCurrent osteoporosis reports2018
CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.
Review in Current osteoporosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Prevalence and determinants of secondary hyperparathyroidism: IMOS-2021.Scientific reports · 2026Article
- Investigation of secondary hyperparathyroidism and its contributing factors in hemodialysis patients: A cross-sectional study.Journal of education and health promotion · 2026Article
- Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025Review
- TheBiomedicines · 2024Review
- The effect of a training program on the self-care efficacy of hemodialysis patients with mineral and bone disorders: A quasi-experimental study.Health science reports · 2023Article
- Study on the correlation between mineral bone metabolism and CRP in patients with SHPT during perioperative period.Immunity, inflammation and disease · 2023Article
- Relative comparison of chronic kidney disease-mineral and bone disorder rat models.Frontiers in physiology · 2023Article
- Bone Disease in Chronic Kidney Disease and Kidney Transplant.Nutrients · 2022Review
- Magnesium-A More Important Role in CKD-MBD than We Thought.Diagnostics (Basel, Switzerland) · 2022Review
- Toxic Effects of Indoxyl Sulfate on Osteoclastogenesis and Osteoblastogenesis.International journal of molecular sciences · 2021Review
- Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management.Cureus · 2021Review
- Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Article
- FGF23, Biomarker or Target?Toxins · 2019Review
- Association betweenPeerJ · 2019Article
- Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective.Indian journal of endocrinology and metabolismReview
- Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism.AACE clinical case reportsArticle
- The disparity of measuring bone mineral content using bioimpedance and dual-energy absorptiometry in the context of hyperparathyroidism.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAlthough we have seen tremendous advances in the comprehension of CKD-MBD pathophysiology during the last few years, this was not accompanied by a significant change in mortality rate and quality of life. This review will address the traditional and updated pathophysiology of CKD-MBD along with the therapeutic limitations that affect CKD-MBD and proposed alternative treatment targets. RECENT
findingsAn innovative concept brings the osteocyte to the center of CKD-MBD pathophysiology, in contrast to the traditional view of the skeleton as a target organ for disturbances in calcium, phosphate, parathyroid hormone, and vitamin D. Osteocytes, through the synthesis of FGF-23, sclerostin, among others, are able to interact with other organs, making bone an endocrine organ. Thus, osteocyte dysregulation might be an early event during the course of CKD. This review will revisit general concepts on the pathophysiology of CKD-MBD and discuss new perspectives for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.